These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12532338)

  • 1. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer.
    DuHadaway JB; Lynch FJ; Brisbay S; Bueso-Ramos C; Troncoso P; McDonnell T; Prendergast GC
    J Cell Biochem; 2003 Feb; 88(3):635-42. PubMed ID: 12532338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells.
    Wechsler-Reya R; Elliott K; Herlyn M; Prendergast GC
    Cancer Res; 1997 Aug; 57(15):3258-63. PubMed ID: 9242458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The membrane-tubulating potential of amphiphysin 2/BIN1 is dependent on the microtubule-binding cytoplasmic linker protein 170 (CLIP-170).
    Meunier B; Quaranta M; Daviet L; Hatzoglou A; Leprince C
    Eur J Cell Biol; 2009 Feb; 88(2):91-102. PubMed ID: 19004523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and nuclear localization of ErbB3 in prostate cancer.
    Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
    Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
    Partin AW; Briggman JV; Subong EN; Szaro R; Oreper A; Wiesbrock S; Meyer J; Coffey DS; Epstein JI
    Urology; 1997 Nov; 50(5):800-8. PubMed ID: 9372899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical localization of prostate carcinoma-associated antigens.
    Wright GL; Beckett ML; Starling JJ; Schellhammer PF; Sieg SM; Ladaga LE; Poleskic S
    Cancer Res; 1983 Nov; 43(11):5509-16. PubMed ID: 6193873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
    Lucas JM; True L; Hawley S; Matsumura M; Morrissey C; Vessella R; Nelson PS
    J Pathol; 2008 Jun; 215(2):118-25. PubMed ID: 18338334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate.
    Mora GR; Olivier KR; Cheville JC; Mitchell RF; Lingle WL; Tindall DJ
    Mol Cancer Res; 2004 Feb; 2(2):115-28. PubMed ID: 14985468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of differentially expressed nucleolar transforming growth factor-beta1 target (DENTT) in adult mouse tissues.
    Martínez A; Ozbun LL; Angdisen J; Jakowlew SB
    Dev Dyn; 2002 Jun; 224(2):186-99. PubMed ID: 12112471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
    Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
    Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells.
    Song J; Aumüller G; Xiao F; Wilhelm B; Albrecht M
    Prostate; 2004 Mar; 58(4):394-405. PubMed ID: 14968440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
    Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y
    J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
    Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
    Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
    Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
    J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.
    Dong Y; Bui LT; Odorico DM; Tan OL; Myers SA; Samaratunga H; Gardiner RA; Clements JA
    Endocr Relat Cancer; 2005 Dec; 12(4):875-89. PubMed ID: 16322328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor.
    Sakamuro D; Elliott KJ; Wechsler-Reya R; Prendergast GC
    Nat Genet; 1996 Sep; 14(1):69-77. PubMed ID: 8782822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
    Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
    Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody.
    Perk J; Gil-Bazo I; Chin Y; de Candia P; Chen JJ; Zhao Y; Chao S; Cheong W; Ke Y; Al-Ahmadie H; Gerald WL; Brogi E; Benezra R
    Cancer Res; 2006 Nov; 66(22):10870-7. PubMed ID: 17108123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.